DDInter1544 DDInter1733
Prucalopride is a dihydrobenzofurancarboxamide derivative from the benzofurane family that selectively stimulates 5-HT4 receptors and thus, it presents enterokinetic properties. The high selectivity of prucalopride allowed further development as it prevented the cardiac adverse reactions observed due to non-target effects of precedent therapies. Prucalopride was developed by Shire Development LLC and approved for use in Europe in 2009, in Canada on December 7, 2011 and by the FDA on December 17, 2018.
Suvorexant is a selective dual antagonist of orexin receptors OX1R and OX2R that promotes sleep by reducing wakefulness and arousal. It has been approved for the treatment of insomnia.
Suvorexant {u} may cause a minor interaction that can limit clinical effects when taken with {v} Naloxegol
Suvorexant {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Clofedanol
Suvorexant {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Rucaparib
Suvorexant {u} may lead to a major life threatening interaction when taken with {v} Cobicistat
Suvorexant {u} may lead to a major life threatening interaction when taken with {v} Imatinib
Suvorexant may cause a minor interaction that can limit clinical effects when taken with Naloxegol
Suvorexant may cause a moderate interaction that could exacerbate diseases when taken with Clofedanol
Suvorexant may cause a moderate interaction that could exacerbate diseases when taken with Rucaparib
Suvorexant may lead to a major life threatening interaction when taken with Cobicistat
Suvorexant may lead to a major life threatening interaction when taken with Imatinib